期刊文献+

国家基本药物目录(2018年版)中抗菌药物适应证用法用量比对分析 被引量:1

Comparative analysis of indications usage and dosage of antibacterial agents in 2018 Edition of National Essential Medicine List
下载PDF
导出
摘要 目的通过比对和分析《国家基本药物目录》(2018版)(2018版基药目录)中抗菌药物适应证、用法用量与国内外参考资料的差异,了解差异类型和产生原因,同时为药品说明书修订提供参考,促进基本药物的合理使用。方法2018版基药目录中抗菌药物按规定剂型展开,以药品国内说明书适应证和用法用量为基础,与美国食品药品监督管理局(FDA)药品说明书和国内外5部权威药学专著进行比对,采用Excel 2007软件进行数据统计分析。结果按规定剂型展开药品93种,与各参考资料相比,适应证完全一致的比例为17%~45%,差异主要类型有适应证有增减;用法用量完全一致的比例为0~45%,差异主要类型为国外参考资料中肌肉注射和静脉滴注的剂量相同,而国内参考资料中多为不一致;适应人群用药详细信息不同;单次剂量不同;给药频次不同。结论2018版基药目录中抗菌药物说明书适应证和用法用量与国内外参考资料相比差异较大,产生原因多样,亟待采取有效的管理措施,以保障基本药物的合理使用。 Objective To compare and analyze the differences in indications,usage and dosage of antibacterial agents between National Essential Medicine List(2018 Edition)(NEML)and several drug information published in China or other countries,so as to investigate the types and causes of differences,provide suggestion for future revision of drug labels,and promote rational use of essential medicine.Methods The indications,dosage and usage of antibacterial agents in 2018 Edition NEML,categorized by uniform preparation formulation,were compared with descriptions in FDA drug labels and five reputed domestic books,using Excel 2007 for data calculation and statistical analysis.Results In total,93 antibacterial agents categorized by uniform preparation formulation in 2018 Edition NEML,were compared with the reference materials.The rate of complete consistency in indications was 17%-45%,with differences chiefly resulting from addition and/or withdrawal of indications.The rate of complete consistency in dosage and usage was 0-45%,with differences chiefly in the intramuscular and intravenous injection dosage which was identical to international descriptions but varied substantially with Chinese drug labels,the detailed dosage information for target population,the single dose,and dosing intervals.Conclusion The indications,dosage and usage of antibacterial agents in 2018 Edition NEML are significantly different from the information in other Chinese or international counterparts due to multiple reasons.Effective managerial measures should be adopted to ensure rational use of essential medicine.
作者 赵瑞玲 张云霞 王晶 侯毅 Zhao Ruiling;Zhang Yunxia;Wang Jing;Hou Yi(Department of Pharmacy,Children's Hospital of Shanxi Province,Taiyuan 030013,China)
出处 《中国药物与临床》 CAS 2020年第5期697-700,共4页 Chinese Remedies & Clinics
基金 山西省儿童医院山西省妇幼保健院院内科研基金(201623)。
关键词 基本药物 抗菌药 适应症 用法用量 Essential medicine Anti-bacterial agents Andication Susage and dosage
  • 相关文献

参考文献3

二级参考文献27

  • 1FDA.Federal Food, Drug, and Cosmetic Act (FD&C Act). SUB- CHAPTER II-DEFINITIONS ~ 321. Definitions; generally.[S/OL~ (1938-01-25) [2014-5-27 ] .http ://www.gpo.gov/fdsys/pkg/ USCODE-2010-title21/html/USCODE-2010-title21 -chap9- subchaplI.htm.
  • 2FDA.ELECTRONIC CODE OF FEDERAL REGULATIONS ~ 201.56 Requirements on content and format of labeling for human prescription drug and biological products[S/OL]. (2006-01- 24) [2014-05-27].bttp://www.ecfr.gov/cgi-bin/text-idx?SID= 61 f3858421 a315badeda356dc448754d&node=21:4.0.1.1.2.2.1.4& rgn=div8.
  • 3FDA. Food and Drug Administration Amendments Act of 2007Ti- tle IX-Enhanced authorities regarding postmarket safety of drugs. sec. 901. postmarket studies and clinical trials regarding human dmgs; risk evaluation and mitigation strategies~[S/OL].(2007-09-27) 12014- 05-27 ].http://www. gpo. gov/fdsys/pkg/PLAW- 110pub185/html/ PLAW-110pub185.htm.
  • 4FDA.Code of Federal Regulations. Title 21 FOOD AND DRUGSSec. 314.70 Supplements and other changes to an approved appli- cation [S/OL]. (2013-04-01) [2014-05-27].http://www.accessdata. fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.70.
  • 5FDA.Guidance for Industry Labeling for Human Prescription Drug and Biological Products-Implementing the PLR Content and Format Requirements[S/OL]. (2013-01) [2014-05-27].http:/Iwww.fda.gov/ downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm075082.pdf.
  • 6FDA. ELECTRONIC CODE OF FEDERAL REGULATIONS. 21CFR 201.57 Specific requirements on content and format of labeling for human prescription drag and biological products describedin ~ 201.56(b)(1). [S/OL]. (2006-01-24)[2014-05-27].http://www. ecfr.gov/cgi-bin/text-idx ?SID=06546f2bSeSba482 f98c864a6941 - b2bl&node=21:4.0.1.1.2.2.1.4&rgn=div8.
  • 7FDA. CFR-Code of Federal Regulations Title 21. PART 208 MEDICATION GUIDES FOR PRESCRIPTION DRUG PRODUCTS. [S/OL].(2013-04) [2014-05-27] ahttp://www.accessdat,a.fd,xgov/scripts/ cdrh/cfdocs/cfcfr/CFRSearch.cfm ?CFRPart=208& showFR= 1 & sub- partNode=21:4.0.1.1.8.1.
  • 8Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature [J]. Pediatr Dermatol,2008,25(2): 168 - 173.
  • 9Chang LC, Haggstrom AN, Drolet BA, characteristics of infantile hemangiomas: et al. Growth implications for management [J].Pediatrics, 2008,122(2):360-367.
  • 10Weiss I, Lipari BA, Meyer L, et al. Current treatment of parotid hemangiomas [J]. Laryngoscope, 2011,121(8):1642-1650.

共引文献81

同被引文献20

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部